Literature DB >> 2325135

Effects of nicotinic acid and mepacrine on fatty acid accumulation and myocardial damage during ischemia and reperfusion.

M van Bilsen1, G J van der Vusse, P H Willemsen, W A Coumans, T H Roemen, R S Reneman.   

Abstract

To assess the nature of ischemia- and reperfusion-induced lipid changes and their consequences for myocardial function and integrity, Krebs-Henseleit perfused, isolated, working rat hearts were treated with nicotinic acid or mepacrine, putative inhibitors of triacylglycerol and phospholipid hydrolysis, respectively. In non-treated hearts 60 min ischemia resulted in a marked rise in myocardial fatty acid (FA) content. The FA content sharply increased further during 30 min reperfusion. Seven out of 16 (44%) hearts fibrillated continuously during reperfusion. Post-ischemic recovery of cardiac output (CO) of the non-fibrillating hearts amounted to 68 +/- 15% of the preischemic value. Nicotinic acid (10 microM) significantly reduced FA accumulation during ischemia (P less than 0.05), but not during reperfusion (0.05 less than P less than 0.10). Post-ischemic recovery of CO was improved (87 +/- 12%). This was neither associated with preservation of myocardial adenine nucleotide content, nor significant reduction of enzyme release. Mepacrine (1 microM) completely abolished reperfusion arrhythmias and improved recovery of CO (88 +/- 7% of pre-ischemic value). The reduction of FA content in ischemic and reperfused hearts did not reach the level of significance. Enzyme release was not attenuated. At 10 microM, mepacrine completely prevented accumulation of FAs during ischemia and reperfusion, abolished reperfusion-arrhythmias, and reduced enzyme release. No concomitant preservation of adenine nucleotides was observed. In conclusion, nicotinic acid and mepacrine are able to reduce ischemia- and reperfusion-induced changes in myocardial lipid metabolism. In addition, both drugs improve post-ischemic functional recovery. It remains to be established whether these effects are causally related.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2325135     DOI: 10.1016/0022-2828(90)91112-k

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  5 in total

Review 1.  Phospholipase A2-mediated hydrolysis of cardiac phospholipids: the use of molecular and transgenic techniques.

Authors:  L J De Windt; R S Reneman; G J Van der Vusse; M Van Bilsen
Journal:  Mol Cell Biochem       Date:  1998-03       Impact factor: 3.396

Review 2.  New hopes from old drugs: revisiting DNA-binding small molecules as anticancer agents.

Authors:  Katerina Gurova
Journal:  Future Oncol       Date:  2009-12       Impact factor: 3.404

Review 3.  Modulation of Hypercholesterolemia-Induced Oxidative/Nitrative Stress in the Heart.

Authors:  Csaba Csonka; Márta Sárközy; Márton Pipicz; László Dux; Tamás Csont
Journal:  Oxid Med Cell Longev       Date:  2015-12-14       Impact factor: 6.543

4.  Effect of Omacor on HRV parameters in patients with recent uncomplicated myocardial infarction - A randomized, parallel group, double-blind, placebo-controlled trial: study design [ISRCTN75358739].

Authors:  Cornel Pater; Daniele Compagnone; Joachim Luszick; Cees-Nico Verboom
Journal:  Curr Control Trials Cardiovasc Med       Date:  2003-10-15

5.  Theranostic Platforms Based on Silica and Magnetic Nanoparticles Containing Quinacrine, Chitosan, Fluorophores, and Quantum Dots.

Authors:  Dmitry V Korolev; Galina A Shulmeyster; Natalia V Evreinova; Maria S Syrovatkina; Maria S Istomina; Victor N Postnov; Ilia V Aleksandrov; Aleksandr S Krasichkov; Michael M Galagudza
Journal:  Int J Mol Sci       Date:  2022-01-15       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.